Taiwan’s Lotus Pharma inks biosimilars agreement with Alvotech for US and selected Asian markets

Taiwan-based Lotus Pharmaceutical Co. (TW: 1795) has announced a strategic licensing and commercialisation agreement with Alvotech, covering two of Alvotech’s candidates in the United States and selected Asian markets: AVT34, a proposed biosimilar to Imfinzi (durvalumab), and AVT87, a proposed biosimilar to Hemlibra (emicizumab).

(25 August, 2026, BioSpectrum Asia)
More…